[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594573":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":28,"locations":36,"responsibleParty":55,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":18,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":18,"overallStatus":39,"whyStopped":18,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Grit Biotechnology","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GT719 Injection treatment group","EXPERIMENTAL","GT719 Injection",[13],"Biological: GT719 Injection",[15],{"type":16,"name":11,"description":11,"armGroupLabels":17,"otherNames":18},"BIOLOGICAL",[9],null,[20,24,26],{"name":21,"affiliation":22,"role":23},"Wei Wang","Tongji Hospital","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":22,"role":23},"Daishi Tian",{"name":27,"affiliation":22,"role":23},"Chuan Qin",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","+8613607178809","tiands@tjh.tjmu.edu.cn",{"name":21,"role":30,"phone":34,"phoneExt":18,"email":35},"+86-27-83662640","wwang@tjh.tjmu.edu.cn",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":18,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","China","CN",{"type":45,"coordinates":46},"Point",[47,48],114.26667,30.58333,{"lat":48,"lon":47},[51,52,53,54],{"name":25,"role":30,"phone":31,"phoneExt":18,"email":32},{"name":21,"role":23,"phone":18,"phoneExt":18,"email":18},{"name":25,"role":23,"phone":18,"phoneExt":18,"email":18},{"name":27,"role":23,"phone":18,"phoneExt":18,"email":18},{"type":56,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[58],{"name":22,"class":59},"OTHER","100594573","phase-1-gt719-injection-for-recurrentrefractory-antibody-mediated-neurological-immune-diseases-100594573",false,"NCT07021209","GT719 Injection for Recurrent\u002FRefractory Antibody-mediated Neurological Immune Diseases","A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent\u002FRefractory Antibody-mediated Neurological Immune Diseases","Inclusion Criteria:\n\n* Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.\n* Expected survival period\\>12 weeks.\n* Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment.\n\nExclusion Criteria:\n\n* History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation.\n* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.\n* Received systemic corticosteroids at a dose of ≥10 mg\u002Fday prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.","ALL","18 Years","75 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent\u002Frefractory antibody-mediated neurological immune diseases.",[78],"Neurological Autoimmune Diseases","2025-09-08",{"date":81,"type":82},"2025-09-15","ACTUAL",{"date":84,"type":82},"2025-01-14",{"date":86,"type":72},"2028-01-13",{"name":5,"class":6},1]